Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jamison L. VanBlaricom
Observed names:
J. VanBlaricom,
Jamison L VanBlaricom,
Jamison VanBlaricom
Institution:
Mayo Clinic
Observed institution:
Mayo Clinic
OpenAlex ID:
A5046932288
LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer
2018
·
Qing Zhang
, Xiaonan Hou
, et al.
·
Cancers
·
53
PDF
Drug-induced nuclear cathepsin L (nCTSL) defines a targetable DNA damage response axis and PARP inhibitor sensitivity in ovarian cancer
2026
·
Prabhu Thirusangu
, Ling Jin
, et al.
·
Cell Communication and Signaling
·
1
Abstract A050: Role of drug induced nuclear CTSL (nCTSL) in DNA damage response in cancer- therapeutic implications
2025
·
Prabhu Thirusangu
, Ling Jin
, et al.
·
Cancer Research
·
1
Gemcitabine and novel Chk1 inhibitor GDC-0575 demonstrate synergistic effect against high-grade serous ovarian cancer in 3D cell culture, PDX models and patient tumors
2020
·
S.R. DeJong
, X. Hou
, et al.
·
Gynecologic Oncology
·
1
Nuclear cathepsin L induces DNA damage by regulating DNA repair factors in ovarian cancer
2026
·
Prabhu Thirusangu
, Upasana Ray
, et al.
·
Oncogene
PDF
Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer
2026
·
Prabhu Thirusangu
, Ling Jin
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Abstract 5058: Impact of dexamethasone on chemotherapy response in ovarian cancer
2023
·
Annapoorna Venkatachalam
, Cristina Correia
, et al.
·
Cancer Research
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
2016
·
Beverly Long
, Xiaonan Hou
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
8
Citation count:
56
H-index:
1
I10-index:
1
Year
Topic
Type
